QualityDipStocks / Health Care · Medical instruments
MiniMed Group MMED
Outside our quality screen, so we don’t track its dips. It’s 21% below its 52-week high.
Outside our quality screen. No fair value estimate for now: its free cash flow is negative.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for MMED: negative free cash flow. We’d rather show nothing than a made-up number.
How it ranks
Where MMED stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Not in the top quarter on any of these 3 measures
- Free cash flow yield−6% · free cash flow vs market capLowest 6%of 1,391
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 1,836
- Operating margin−5.3% · of sales kept as operating profitLowest 7%of 1,288
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 2 of 5
GrowthSales compounded 12% a year from FY2024 to FY2026.
ValuationPrice / book of 1.5×, below the 5.2× median for the 217 Health Care companies we cover.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$316M over the last 12 months), so there’s no cash-flow value under the price.
ProfitabilityLost $314M over the last 12 months (net income, SEC filings).
Cash returnsShare count up 11.2% in a year: existing holders are being diluted.
ProfitabilityLoses money at the operating line: −5% operating margin over the last 12 months.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%.
All fundamentals
FCF yield -6.0% · ROE -9%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −6.0%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 1.64×
- Price / book
- 1.46×
- Market cap
- $5.3Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $3.2B
- Sales growth, 12 months
- n/ano year-ago 12-month revenue
- Sales growth, 3 yrs
- +12.1%/yrfrom FY2024
- Diluted EPS, 12 months
- −$1.22
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$314M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 53.9%
- Operating margin
- −5.3%
- Net margin
- −9.7%
- FCF margin
- −9.8%
- Return on equity
- −9%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $207M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- −$316M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +11.2%diluted shares vs a year ago
- Stock-based comp
- $47M
Trailing 12 months to Jul 31, 2026; balance sheet at Jul 31, 2026. From MiniMed Group’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.3B · Sales +17%
- Free cash flow, 12 months−$0.3B
- Free-cash-flow yield-6.0%
- Gross margin57%
- Operating margin0%
- Return on invested capital0%
- Return on equity−9%
- Sales growth (latest quarter vs year-ago quarter)+17%
- Net debt / EBITDA−0.5×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $18.90
- 52-wk lowlowest close, 1 year$10.80−42.9%
- PriceMon Nov 2 close$18.90you are here
- 52-wk highhighest close, 1 year$23.84+26.1%
Momentum & 52-week range
5 days +1.3%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
MMED is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on MiniMed Group in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Medical instruments
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.